Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular function

Back

ESC Professional Premium Access

Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular function

Session: Cardio-oncology: predicting adverse effects and prognosis

Topic: Cardio-Oncology

Speaker: Doctor M. Slieman (Tel Aviv, IL)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Moaad Slieman

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

0 follower

9 more presentations in this session

Adverse Myocardial and vascular side effects of Immune Checkpoint Inhibitors: a prospective multimodal cardiovascular assessment (AMICI study)

Speaker: Doctor M. Mirabel (Paris, FR)

Cardiovascular outcomes in acute coronary syndrome patients with cancer: a statewide population-linkage study

Speaker: Doctor C. Yu (Toronto, CA)

The CTOX-Score, a clinical risk prediction tool for cardiovascular toxicity secondary to cancer therapies

Speaker: Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)

Fibroblast activation in cardio-oncology

Speaker: Doctor K. Loganath (Edinburgh, GB)

Sodium-glucose co-transporter-2 inhibitors : a potential cardioprotective agent?

Speaker: Doctor T. Georgopoulou (Heraklion, GR)

Access the full session

Cardio-oncology: predicting adverse effects and prognosis

Speakers: Doctor M. Slieman, Doctor M. Mirabel, Doctor C. Yu, Doctor J. Gonzalez Juanatey, Doctor K. Loganath...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources